Bank of New York Mellon’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-225,493
| Closed | -$5.43M | – | 4528 |
|
|
2023
Q1 | $5.43M | Sell |
225,493
-39,639
| -15% | -$497K | ﹤0.01% | 2259 |
|
|
2022
Q4 | $2.8M | Buy |
265,132
+51,102
| +24% | +$412K | ﹤0.01% | 2662 |
|
|
2022
Q3 | $963K | Buy |
214,030
+41,672
| +24% | +$190K | ﹤0.01% | 3219 |
|
|
2022
Q2 | $690K | Sell |
172,358
-32,555
| -16% | -$154K | ﹤0.01% | 3402 |
|
|
2022
Q1 | $1.5M | Sell |
204,913
-10,850
| -5% | -$64.9K | ﹤0.01% | 3087 |
|
|
2021
Q4 | $1.21M | Sell |
215,763
-12,806
| -6% | -$81.3K | ﹤0.01% | 3272 |
|
|
2021
Q3 | $1.46M | Buy |
228,569
+30,770
| +16% | +$198K | ﹤0.01% | 3188 |
|
|
2021
Q2 | $1.67M | Buy |
197,799
+17,770
| +10% | +$143K | ﹤0.01% | 3119 |
|
|
2021
Q1 | $1.89M | Buy |
180,029
+3,390
| +2% | +$47.7K | ﹤0.01% | 2955 |
|
|
2020
Q4 | $2.99M | Buy |
176,639
+5,123
| +3% | +$76.8K | ﹤0.01% | 2613 |
|
|
2020
Q3 | $2.2M | Buy |
171,516
+10,344
| +6% | +$131K | ﹤0.01% | 2613 |
|
|
2020
Q2 | $2.27M | Buy |
161,172
+138,666
| +616% | +$1.75M | ﹤0.01% | 2606 |
|
|
2020
Q1 | $207K | Sell |
22,506
-25,000
| -53% | -$322K | ﹤0.01% | 3729 |
|
|
2019
Q4 | $708K | Buy |
47,506
+35,428
| +293% | +$316K | ﹤0.01% | 3404 |
|
|
2019
Q3 | $82K | Buy |
+12,078
| New | +$122K | ﹤0.01% | 4054 |
|
Other funds holding PRVB
Bank of New York Mellon's PRVB Position: Q2 2023 in Review
Bank of New York Mellon sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 225,493 shares — an estimated $5.43M sold.
Bank of New York Mellon first reported a position in PRVB in Q3 2019 and held it in 15 quarters. The position peaked at $5.43M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Bank of New York Mellon reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Bank of New York Mellon sold 225,493 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $5.43M.
- Bank of New York Mellon first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Bank of New York Mellon's Provention Bio, Inc. Common Stock position peaked at $5.43M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.